Last reviewed · How we verify
Methyprednisolone sodium succinate
Methylprednisolone sodium succinate is a corticosteroid that suppresses the immune system by inhibiting the production of inflammatory cytokines.
Methylprednisolone sodium succinate is a corticosteroid that suppresses the immune system by inhibiting the production of inflammatory cytokines. Used for Severe asthma attacks, Severe allergic reactions (anaphylaxis), Severe skin conditions (such as psoriasis or eczema).
At a glance
| Generic name | Methyprednisolone sodium succinate |
|---|---|
| Also known as | Methylprednisolone |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to glucocorticoid receptors in the cytoplasm, which then translocate to the nucleus and inhibit the transcription of inflammatory genes. This leads to a decrease in the production of pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha, resulting in reduced inflammation and immune response.
Approved indications
- Severe asthma attacks
- Severe allergic reactions (anaphylaxis)
- Severe skin conditions (such as psoriasis or eczema)
- Severe respiratory conditions (such as COPD or bronchitis)
- Severe inflammatory conditions (such as rheumatoid arthritis or lupus)
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Increased blood pressure
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: